Cwm, LLC Affimed N.V. Transaction History

Cwm, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 27, 2022	SELL	$1.96 - $3.32 $3,183 - $5,391	-1,624 Reduced 43.27%	2,129 $4,000
Q2 2022 Jul 28, 2022	BUY	$2.27 - $4.86 $3,790 - $8,116	1,670 Added 80.17%	3,753 $10,000
Q3 2020 Sep 15, 2021	BUY	$3.26 - $4.73 $6,790 - $9,852	2,083 New	2,083 $18,000
Q3 2020 Oct 19, 2020	SELL	$3.26 - $4.73 $6,790 - $9,852	-2,083 Closed	0 $0
Q2 2020 Sep 15, 2021	BUY	$1.58 - $4.63 $3,291 - $9,644	2,083 New	2,083 $18,000
Q2 2020 Jul 22, 2020	SELL	$1.58 - $4.63 $3,291 - $9,644	-2,083 Closed	0 $0
Q1 2020 Sep 15, 2021	BUY	$1.44 - $3.02 $2,999 - $6,290	2,083 New	2,083 $18,000
Q1 2020 Apr 28, 2020	SELL	$1.44 - $3.02 $2,999 - $6,290	-2,083 Closed	0 $0
Q4 2019 Sep 14, 2021	BUY	$2.25 - $3.07 $4,686 - $6,394	2,083 New	2,083 $18,000
Q4 2019 Jan 27, 2020	SELL	$2.25 - $3.07 $4,686 - $6,394	-2,083 Closed	0 $0
Q3 2019 Sep 14, 2021	BUY	$2.67 - $3.65 $5,561 - $7,602	2,083 New	2,083 $18,000
Q3 2019 Oct 22, 2019	SELL	$2.67 - $3.65 $5,561 - $7,602	-2,083 Closed	0 $0
Q2 2019 Sep 14, 2021	BUY	$2.6 - $4.21 $5,415 - $8,769	2,083 New	2,083 $18,000
Q2 2019 Jul 31, 2019	SELL	$2.6 - $4.21 $5,415 - $8,769	-2,083 Closed	0 $0
Q1 2019 Sep 02, 2021	BUY	$3.05 - $4.34 $6,353 - $9,040	2,083 New	2,083 $0

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

Stay updated on Cwm, LLC with notifications on news.